Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.
Xia S, Chan JF, Wang L, Jiao F, Chik KK, Chu H, Lan Q, Xu W, Wang Q, Wang C, Yuen KY, Lu L, Jiang S.
Xia S, et al. Among authors: chan jf.
Cell Res. 2022 Apr;32(4):404-406. doi: 10.1038/s41422-022-00617-x. Epub 2022 Jan 27.
Cell Res. 2022.
PMID: 35087243
Free PMC article.
No abstract available.